NJC





Cite this: New J. Chem., 2017, 41, 302

Use of apomyoglobin to gently remove heme from a H_2O_2 -dependent cytochrome P450 and allow its reconstitution[†]

Shih-Cheng Chien,^a Osami Shoji,*^{ab} Yoshiko Morimoto^c and Yoshihito Watanabe*^c

The heme of hydrogen peroxide-dependent cytochrome $P450_{BS\beta}$ (P450_{BS\beta}) was removed by apomyoglobin under mild conditions to give apo-P450_{BSβ} without the need for acidic conditions and organic solvents. The circular dichroism spectrum of the apo-P450_{BSβ} was essentially identical to that of holo-P450_{BSβ}, showing a small structural change resulting from the removal of heme using apomyoglobin. The apo-P450_{BSβ} was reconstituted with hemin or manganese protoporphyrin IX (MnPPIX), and the resulting reconstituted P450_{BSβ} catalyzed the one-electron oxidation of guaiacol using hydrogen peroxide as an oxidant. A higher catalytic activity was observed for P450_{BSβ} reconstituted with MnPPIX when *meta*-chloroperoxybenzoic acid (*m*CPBA) was used as the oxidant.

Received (in Montpellier, France) 16th September 2016, Accepted 21st November 2016

DOI: 10.1039/c6nj02882a

www.rsc.org/njc

Introduction

Heme, Fe-protoporphyrin IX, is one of the most important metal complexes in nature, serving as the prosthetic group for hemoproteins that perform diverse functions, including oxygen storage and transport, gas sensing, electron transfer, and catalysis.^{1,2} The properties of hemoproteins largely depend on the nature of heme; therefore, replacement of the heme with heme analogues are expected to drastically change the properties of hemoproteins.³ A variety of reconstituted hemoproteins containing heme analogues, and heme derivatives including different metal ions, chemically modified hemes, and synthetic metal complexes have been constructed with the aim of developing synthetic proteins with (improved) catalytic activity or entirely different functions.^{4,5} To allow the reconstitution of hemoproteins with synthetic metal complexes, the tightly bound heme must be removed to give apoproteins. Noncovalently bound hemes (b-type hemes) can be extracted from hemoproteins using organic solvents such as butan-2-one and acetone under acidic conditions (pH 2-4). Teale et al. first reported the removal of heme from hemoproteins utilizing acid-butanol (pH = 2) to prepare apo forms

^a Department of Chemistry, Graduate School of Science, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8602, Japan. of horse heart and skeletal muscle myoglobin (Mb).⁶ Several methods based on a slight modification of this acid-butanol method have been reported for the preparation of apo forms of hemoproteins such as HRP and P450_{cam} (see Fig. S1 and S2 for these different heme enzyme structures, ESI⁺).^{7,8} However, these methods are not suitable if the hemoproteins as well as their apo-forms are not sufficiently stable in organic solvents and/or under acidic conditions. Although the preparation of apoproteins in bacterial cells has been developed as an alternative, their reconstitution was limited to metal complexes possessing a protoporphyrin IX framework. To avoid the use of harsh chemical treatments in the preparation of apoproteins, and to expand the range of applicable metal complexes to include various synthetic metal complexes, it is important to develop a simple strategy for removing the heme of hemoproteins without the need for organic solvents and acidic conditions.

Cytochrome P450_{BSβ} (P450_{BSβ}) is a hemoprotein that is irreversibly denatured during the preparation of apoprotein under the methods described above. Therefore, it has been believed to be impossible to prepare reconstituted P450_{BSβ}. However, P450_{BSβ} is regarded as a promising candidate for the construction of a biocatalyst because P450_{BSβ} and its unique family, the hydrogen peroxide-dependent P450s, efficiently utilize hydrogen peroxide to catalyze various C–H bond hydroxylations and some other types of oxidation reactions.^{9,10} If the heme of P450_{BSβ} could be replaced with synthetic metal complexes, the properties of the enzymatic reaction catalyzed by P450_{BSβ} could be altered to allow the development of a versatile biocatalyst.

Here we report a simple and useful method for the preparation of apo-P450_{BS β} using apo-Mb under very mild conditions (Scheme 1). We decided to employ apo-Mb as a heme scavenger



View Article Online

E-mail: shoji.osami@a.mbox.nagoya-u.ac.jp

^b Core Research for Evolutional Science and Technology (CREST), Japan Science and Technology Agency, 5 Sanbancho, Chiyoda-ku, Tokyo, 102-0075, Japan

^c Research Center for Materials Science, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8602, Japan. E-mail: p47297a@nucc.cc.nagoya-u.ac.jp

 $[\]dagger$ Electronic supplementary information (ESI) available: Supplementary figures including crystal structures, UV-Vis and CD spectra, the spectrum of purification and the proposed mechanisms of Mn–P450_{BSB} with *m*CPBA. See DOI: 10.1039/c6nj02882a



Scheme 1 Schematic illustration of apo-Mb capturing the native cofactor heme (red with the iron atom in yellow) and subsequently reconstituted with an artificial cofactor (blue with the manganese atom in magenta) to generate a functional enzyme from holo-form H_2O_2 -dependent P450_{BSB}

because it binds strongly to heme and can be readily prepared by the aforementioned acid-organic solvent-methods; the dissociation constant of apo-Mb for heme is reported to be 10^{-14} M^{-1} .¹¹ We also demonstrate that the resulting apo-P450_{BSB} can be reconstituted with manganese protoporphyrin IX (MnPPIX) and that the resulting reconstituted P450_{BSB} exhibits improved one-electron oxidation activity when mCPBA was employed as an oxidant.

Experimental methods

Materials

All chemicals were purchased from commercial sources and used without further purification unless otherwise indicated. Mn(III) protoporphyrin IX chloride was obtained from Frontier Scientific, Inc. (Logan, UT, USA) and used after exchanging its Cl^{-} for BF_4^{-} by treating with AgBF₄. Hydrogen peroxide, dithiothreitol (DTT), ethylene glycol, sodium dodecyl sulfate (SDS), isopropyl-β-D-1-thiogalactopyranoside (IPTG), and kanamycin sulfate were obtained from WAKO Pure Chemical Industries, Ltd (Osaka, Japan). Glycerol, potassium chloride, urea, hydrochloric acid, potassium phosphate, ampicillin sodium salt and phenylmethylsulfonyl fluoride were purchased from Nacalai Tesque Inc. (Kyoto, Japan). Horse skeletal muscle Mb was obtained from Sigma-Aldrich Co. (St. Louis, MO, USA). Concentrations of chemicals described in procedures are the final concentrations.

Measurements

UV-visible (UV-Vis) absorption spectra were recorded on a UV-2600 PC spectrophotometer (Shimadzu Corporation) or an Agilent 8453 equipped with an 89090A thermal controller (Agilent Technologies, Inc.), and the data were collected using screw-capped quartz cuvettes of 1 cm path length. Circular dichroism (CD) spectra were recorded with quartz cuvettes of 0.1 cm path length using a J-720WI spectropolarimeter (Jasco Corporation) equipped with a temperature controller, and the data were recorded from 200 to

260 nm at 24 °C and 20 nm min⁻¹ scan speed, and an average spectrum was produced from four independent consecutive scans. Size distributions were recorded by dynamic light scattering (DLS) using a Nano ZS (Malvern Instruments Ltd) with disposable plastic cuvettes and caps. Inductively coupled plasma-optical emission spectrometer (ICP-OES) measurements were performed on a Varian Vista-Pro ICP Spectrometer (Varian Inc.). The purification procedures described below were carried out using a Bioassist eZ system (Tosoh Corporation). The protein figures were generated using the PyMOL Molecular Graphics System (version 1.8; DeLano Schrödinger, LLC.).

Protein expression and purification

For the expression of recombinant P450_{BS β}, 6× histidine-tagged (6× His-tagged) P450_{BS β} was expressed in the transformed Escherichia coli strain M15. Cells were cultivated at 27 °C in Luria–Bertani medium supplemented with 100 $\mu g m L^{-1}$ of ampicillin and 25 μ g mL⁻¹ of kanamycin. Once the culture reached an optical density at 600 nm (OD₆₀₀) of 0.7-0.8, heme precursor δ -aminolevulinic acid (0.5 mM) was added, and the culture was incubated for an additional 30 min. At $OD_{600} = 1.0-1.2$, gene expression was induced by addition of IPTG (0.1 mM), and cultivation was followed by culturing at 20 °C for 20 h rotating at 80 rpm. Cells were then harvested by centrifugation and lysed in 0.1 M potassium phosphate buffer (pH 7.0) with 0.3 M potassium chloride, 50 mM imidazole, and 20% (v/v) glycerol. Purification of $6 \times$ His-tagged P450_{BSB} was performed by Ni-chelate affinity chromatography (GE Healthcare, Little Chalfont, UK). The protein was further purified using S-200 Sephacryl (GE Healthcare) size exclusion chromatography. An A_{Soret}/A_{280} absorbance ratio ≥ 1 indicated the high purity of the protein, which was also confirmed by SDS-polyacrylamide gel electrophoresis (SDS-PAGE). Reduced CO-difference spectra were used to determine the concentration of P450 by subjecting the purified recombinant protein to sodium dithionite and CO gas.¹² Protein samples were stored at -80 °C for further use.

Preparation of apo-Mb

A heme moiety was extracted from horse skeletal muscle Mb by the butan-2-one extraction according to a published procedure⁶ with slight modifications. The pH of a Mb solution (100 mg Mb in 40 mL Milli-Q water) was adjusted to 2.5 in an ice-water bath using chilled 0.1 M HCl_(aq). The solution was transferred to a separation funnel, and an equal volume of 2-butanone was added. The mixture was gently shaken for 30 s and then allowed to stand for 10 min at 4 °C. The colorless aqueous phase was separated and dialyzed for 24 h at 4 °C against 5 L of Milli-Q water, and then for 24 h against PBS buffer (pH 7.3). Next, the solution was passed through a 0.22 μm filter and stored at 4 $^\circ C$ for further use. The concentration of prepared apo-Mb was spectrophotometrically determined using its extinction coefficient of 15 700 M⁻¹ cm⁻¹ at 280 nm.¹³

Preparation of apo-P450_{BSβ}

The removal of heme from $P450_{BS\beta}$ to prepare apo-P450_{BS\beta} was performed by treating P450_{BSB} with apo-Mb. The reaction was carried out in 0.1 M potassium phosphate buffer (pH 7.0) containing 0.3 M potassium chloride and 20% (v/v) glycerol with P450_{BSβ} (25 mL, 8.5 μ M). Solid Na₂S₂O₄ was dissolved into the solution (1 mg mL⁻¹) at 25 °C to generate reduced P450_{BSβ}. Five equivalents of apo-Mb (25 mL, 42.5 μ M) was added to the reaction buffer, and the final concentration of glycerol was adjusted to 5% using additional PBS buffer. The reaction was maintained in a gas-tight flask for 24 h without stirring. Before purification, 0.02% of Triton X-100 was added to aid the separation of P450_{BSβ} and Mb. Purification of 6× His-tagged apo-P450_{BSβ} was performed by Ni-chelate affinity chromatography to remove holo-Mb and excess apo-Mb. This is the same purification procedure used for recombinant P450_{BSβ} was stored at 4 °C for further use or stored at -80 °C for long-term preservation.

Reconstitution of apo-P450 $_{BSB}$

Reconstitution of apo-P450_{BSβ} was performed by adapting the procedure for apo-P450_{cam}¹⁴ at 25 °C as well as subsequent protein purification at 4 °C. After the preparation of protoporphyrin complex solution, it should be added to apo-P450_{BSβ} buffer immediately. Any delay in the addition of protoporphyrin complex solution to apo-P450_{BSβ} led to incomplete recombination due to its low solubility in water solution.¹³

rFe–P450_{BSβ}. A 7 mL apo-P450_{BSβ} (6 μM) solution at pH 7.0 under an argon atmosphere was combined with urea (2 M), DTT (10 mM), histidine (10 mM), and Triton X-100 (0.02%). The solution was then left to stand for a further 15 min at room temperature. A 50 μL KOH solution (0.1 M) containing hemin (2.5 eq., 2.1 mM) and myristic acid (0.2 mM), diluted tenfold with Milli-Q water, was added dropwise to the solution of apoprotein. The whole reaction was performed in a gas-tight flask for 24 h without stirring. Before purification, an Amicon ultracentrifugal filter was used to remove excess hemin and other chemicals. Purification of $6 \times$ His-tagged rFe–P450_{BSβ} was performed by Ni-chelate affinity chromatography to remove free hemin by the same procedure used for the preparation of recombinant P450_{BSβ}. The final purified rFe–P450_{BSβ} gave a single band on SDS-PAGE.

 $rMn-P450_{BS\beta}$. The insertion of MnPPIX into the apoprotein was carried out using a 7 mL apo-P450_{BSβ} (6 μ M) solution at

pH 7.0 under an argon atmosphere. The apoprotein solution was combined with urea (2 M), DTT (10 mM), histidine (10 mM), and TritonTM X-100 (0.02%), and then left to stand for 15 min at room temperature. A 210 μ L KOH solution (0.1 M) containing MnPPIX(BF₄) (2.5 eq., 0.5 mM, the concentration determined using a ε_{462nm} of 25 000 M⁻¹ cm⁻¹),¹⁵ diluted tenfold with Milli-Q water, was added dropwise to the solution of apoprotein. The whole reaction was then incubated in a gas-tight flask wrapped in aluminum foil for 24 h without stirring. Before purification, an Amicon ultracentrifugal filter was used to remove excess MnPPIX and other chemicals. Purification of $6 \times$ His-tagged rMn–P450_{BS} was performed by Ni-chelate affinity chromatography to remove free MnPPIX by the same procedure as that used for recombinant P450_{BS}. The final purified rMn–P450_{BS} gave a single band on SDS-PAGE, and the $A_{\text{Sort}(381)}/A_{280}$ absorbance ratio was 0.7.

Determination of P450 concentration

The concentration of the recombinant P450_{BSβ} was measured by reduced CO-difference spectroscopy.¹² In the case of rFe–P450_{BSβ} with a higher content of P420 isoform (Fig. S4, ESI†), the concentration was measured by reduced pyridine-hemochrome spectroscopy.¹⁶ The concentrations of holo- and apo-P450 for CD spectroscopy measurements were determined by the Bradford protein assay.¹⁷ rMn–P450_{BSβ} was quantitated from the Bradford protein assay and multiplied by values of A_{soret}/A_{280} .

Guaiacol oxidation

Using H_2O_2 as an oxidant. For each catalytic reaction, the total volume of the mixture was maintained at 1 mL. The reaction was carried out in a 0.1 M potassium phosphate buffer (pH 7.0) at 25 °C in the presence of 50 nM P450, 10 mM guaiacol (30 µL of 0.4 M ethanol solution), and 20 mM *n*-heptanoic acid (50 µL of 0.4 M ethanol solution). Reactions were initiated by the addition of 4 mM hydrogen peroxide (300 µL of 14 mM aqueous solution). Initial oxidation rates were determined by monitoring the absorption change at 470 nm relative to the tetramer of guaiacol with an extinction coefficient of 26 600 M⁻¹ cm^{-1.18} All initial turnover numbers (TONs) are the average of at least three measurements, and are



Fig. 1 Time course of UV-Vis absorption spectra changes during the reactions at 25 °C for 24 h. (A) P450_{BSB} with apo-Mb. Inset: spectral expansion of 480 \sim 600 nm; (B) Reduced P450_{BSB} with apo-Mb.

expressed as nmol product per nmol P450 per min \pm standard deviation.

Using *m*CPBA as an oxidant. The reaction conditions were similar to those described above, except that the oxidant was changed to *m*CPBA and the reaction mixture does not contain *n*-heptanoic acid. The reactions were started by adding 4 mM *m*CPBA (70 μ L of 60 mM ethanol solution) and monitored by the absorption change at 470 nm. The oxidation products were also determined quantitatively, as described previously.

ICP-OES

The iron and manganese contents in rP450_{BS} were determined by ICP-OES. Concentrated samples of purified rFe–P450_{BS} and rMn–P450_{BS} protein were diluted with 0.2 M HNO₃ to 2 mL of 1.5, 3.0, 4.5 and 6.0 μ M for the determinations. The solution was placed in a new glass vial and subjected to ICP-OES *via* a peristaltic pump. The sample was aspirated with argon, passed over plasma, and analyzed for iron and manganese. A control experiment was performed using Milli-Q water as a sample. Commercial calibration standards and multi-element standards (Wako Pure Chemical Industries, Ltd) were used.

Results and discussion

The removal of the heme from $P450_{BSB}$ to prepare apo-P450_{BSB} was performed by treating P450_{BSB} with apo-Mb. When five equivalents of apo-Mb were added to a solution of histidinetagged P450_{BSB} at 25 °C, apparent shifts of the Soret absorption band and Q-band were observed.[‡] The absorption peak of P450_{BSB} at 417 nm shifted to 409 nm, which is readily attributed to the formation of holo-Mb (Fig. 1A). After 24 h incubation, the resulting apo-P450_{BSB} was purified by Ni-chelate affinity chromatography, but a small amount of holo-P450_{BS β} was still observed. To bring the heme transportation to completion, $P450_{BS\beta}$ was reduced using Na₂S₂O₄ because the dissociation rate constant of reduced heme (Fe^{II}) coordinated with cysteine is rapid compared with that of heme (Fe^{III}).¹⁹ DFT calculations also showed a weaker binding of cysteine to ferroheme than to ferriheme. A clear shift of the absorption maxima of heme was again observed after the addition of apo-Mb, and no remarkable change was observed after 24 h (Fig. 1B).

Apo-P450_{BSβ} purified by Ni-chelate affinity chromatography did not show any absorption assignable to heme, indicating that the heme of P450_{BSβ} can be removed completely (Fig. S5, ESI†). Interestingly, the CD spectrum of apo-P450_{BSβ} was essentially identical to that of the holo form, indicating a small structural change upon the removal of the heme (Fig. 2B), while the CD spectra of apoproteins produced by acid–organic solvent methods were generally significantly different from those of the holo form.²⁰ For example, apo-P450_{cam} prepared by the acid–butanone method gave a weaker CD signal, indicative of partial denaturation. The hydrodynamic diameters of holo- and apo-P450_{BSβ} determined by DLS analysis were 4.36 and 5.05 nm, respectively



Fig. 2 Comparisons between holo- and apo-form P450_{BSB}. Holo-P450_{BSB} is shown as a blue solid line and apo-P450_{BSB} as a red solid line. (A) UV-Vis absorption spectra of holo- and apo-P450_{BSB}. (B) CD spectra (0.0025 M) of holo- and apo-P450_{BSB}; the concentrations of protein were calculated using the Bradford method. (C) DLS spectra of holo- and apo-P450_{BSB}.

(Fig. 2C and Fig. S6, ESI[†]), which are consistent with the size of holo-P450_{BSβ} (PDB ID: 3WSP), indicating that there is no appreciable denaturation or aggregation. These results clearly showed that apo-P450_{BSβ} could be prepared using apo-Mb and the resulting apo-P450_{BSβ} retained almost the same conformation as its holo form without denaturation.

With pure apo-P450_{BSB} in hand, we reconstituted it according to the method reported for preparing reconstituted $P450_{cam}$.¹⁴ Initially, apo-P450_{BSB} was reconstituted with heme to confirm that it is possible to reinsert heme into an appropriate position in P450_{BSB} and to fully recover its catalytic activity. A solution of

 $[\]ddagger$ The absorption spectral change was very slow when the reaction of preparing apo-P450_{BS6} was under 4 °C after 24 h incubation (Fig. S3, ESI \ddagger).

apo-P450_{BSβ} was added with 2.5 equivalents of hemin in the presence of 10 mM DTT and 10 mM histidine, and then incubated for 24 h under argon. Reconstituted P450_{BSβ} (rFe–P450_{BSβ}) could be purified by Ni-chelate affinity chromatography. The UV-Vis absorption spectrum showed a Soret peak at 417 nm. The CD spectrum of reconstituted P450_{BSβ} remained similar to those of recombinant P450_{BSβ} and α -helical proteins (Fig. S7, ESI[†]).

rFe–P450_{BSβ} exhibited catalytic activity similar to that of native P450_{BSβ} for the one-electron oxidation of guaiacol with the assistance of *n*-heptanoic acid, which accelerates the generation of active species of P450_{BSβ} because the carboxylate of *n*-heptanoic acid serves as an acid–base catalyst.²¹ The initial TON (nmol product per nmol P450 per min) of one-electron oxidation of guaiacol by rFe–P450_{BSβ} with heptanoic acid was estimated to be 3150, which is almost the same as that of P450_{BSβ} under similar conditions (Table 1).²² These results indicate that apo-P450_{BSβ} prepared using apo-Mb can be reconstituted with heme and that the reconstituted rFe–P450_{BSβ} has a catalytic activity comparable to that of recombinant P450_{BSβ}.

Given that apo-P450_{BSβ} could be reconstituted with heme, we have attempted to reconstitute apo-P450_{BSβ} with MnPPIX in a similar manner, and obtained P450_{BSβ} reconstituted with MnPPIX (rMn–P450_{BSβ}). The CD spectrum of rMn–P450_{BSβ} confirmed that rMn–P450_{BSβ} had the same protein structure as P450_{BSβ} (Fig. 3 and Fig. S7, ESI†). The Soret absorption band of rMn–P450_{BSβ} was observed at 381 nm, which corresponded to that of P450_{cam} reconstituted with MnPPIX (Fig. 3).^{23,24} ICP-OES showed that 70% of the apo-P450_{BSβ} was reconstituted with MnPPIX. The UV-Vis absorbance ratio ($A_{\text{Soret}(381)}/A_{280}$) of rMn–P450_{BSβ} was consistent with 70% reconstitution.

The catalytic activity of rMn–P450_{BSβ} for one-electron oxidation of guaiacol using hydrogen peroxide as an oxidant was examined, but the TON was very low at 40 min⁻¹. In contrast, when *m*CPBA was used as the oxidant, the catalytic activity was improved (2850 min⁻¹) compared with that of recombinant P450_{BSβ} (Table 1). On the other hand, hydroxylation of cyclohexane was not catalyzed by neither recombinant P450_{BSβ} nor rFe–P450_{BSβ}.

Table 1 Catalytic activity for one-electron oxidation of guaiacol by different oxidants with recombinant and reconstituted P450_{BSB}.^c The units of catalytic activity are described as the TON (all values are the average of five measurements and are expressed in terms of nmol product per nmol P450 per min \pm standard deviation)

OH OCH ₃ P450s oxidant guaiacol (H ₂ O ₂ or <i>m</i> CPBA)	OCH ₃ P450s oxidant (H ₂ O ₂ or mCPBA	
	TON (min ⁻¹)	
Enzyme protein	$H_2O_2^a$	mCPBA
P450 _{BSβ} rFe-P450 _{BSβ} rMn-P450 _{BSβ}	3750^b 3150 ± 50 40 ± 8	$\begin{array}{c} 113 \pm 5 \\ - \\ 2860 \pm 40 \end{array}$

^{*a*} Heptanoic acid assisted these catalytic experiments. ^{*b*} The value of TON is adapted from *Angew. Chem., Int. Ed.*, 2007, **46**, 3656–3659. ^{*c*} For the proposed oxidation mechanism of guaiacol with P450, see Scheme S1, ESI.



Fig. 3 UV-Vis absorption spectrum (black line) of rMn-P450_{BSB} in 0.1 M potassium phosphate buffer (pH 7.0) containing 0.3 M KCl and 20% (v/v) glycerol. The Soret band from MnPPIX in the deep pocket of the active site of P450_{BSB} was at 381 nm, and there was no signal of free MnPPIX or adherent (noncovalently bound) MnPPIX at the surface of P450_{BSB} in the UV-Vis spectrum. The $A_{Soret(381)}/A_{280}$ absorbance ratio was 70%. The CD spectrum showed that rMn-P450_{BSB} remained in the same α -helix structure as the recombinant P450_{BSB}. Inset: CD spectrum (red line) of rMn-P450_{BSB} in the same potassium phosphate buffer.

We also examined the hydroxylation of cyclohexane by rMn–P450_{BSβ} with *m*CPBA, but no product was detected, suggesting either the Mn^{IV}=O, not the Mn^V=O, species generated by homolytic cleavage of Mn^{III}–OOR or very rapid reduction of Mn^V=O under the conditions and eventually Mn^{IV}=O is responsible for oneelectron oxidation by rMn–P450_{BSβ} in the presence of *m*CPBA (Scheme S2, ESI†).²⁵

Conclusions

We have demonstrated that apo-P450_{BS β} can be prepared using apo-Mb as a heme scavenger without subjecting the proteins to harsh and denaturing conditions. Although the preparation of apo-P450s and their reconstitution is generally difficult, the heme of P450_{BSB} was completely removed by apo-Mb to give pure apo-P450_{BSB} that could be reconstituted with MnPPIX. The holo-, apo-, rFe- and rMn-P450_{BSβ} remained as analogous α -helical structures, in contrast to other reported reconstituted P450s and their apo-P450s prepared using the acid-butanone method²⁰ or incubation with hydrogen peroxide.²⁶ Although we focused on the preparation of apo-P450_{BSB}, other P450s whose apo-forms are difficult to prepare by conventional acid-organicsolvent methods may also be potent targets for our methodology. Furthermore, we believe that this method is useful to selectively remove the heme of hemoproteins containing other cofactors such as flavin derivatives or iron-sulfur clusters.

Acknowledgements

This work was supported by Grants-in-Aid for Scientific Research (S) to Y. W. (24225004) from the Ministry of Education, Culture, Sports, Science, and Technology (Japan) and CREST, Japan Science and Technology Agency.

Notes and references

- 1 K. K. Kadish, L. M. Smith and R. Guilard, *The Porphyrin Handbook*, Academic Press, San Diego, USA, 2000.
- 2 S. Schneider, J. Marles-Wright, K. H. Sharp and M. Paoli, *Nat. Prod. Rep.*, 2007, **24**, 621–630.
- 3 L. Fruk, C. H. Kuo, E. Torres and C. M. Niemeyer, *Angew.* Chem., Int. Ed., 2009, **48**, 1550–1574.
- 4 H. Sato, T. Hayashi, T. Ando, Y. Hisaeda, T. Ueno and Y. Watanabe, *J. Am. Chem. Soc.*, 2004, **126**, 436–437.
- 5 T. Hayashi, Y. Hitomi, T. Ando, T. Mizutani, Y. Hisaeda, S. Kitagawa and H. Ogoshi, *J. Am. Chem. Soc.*, 1999, **121**, 7747–7750.
- 6 F. W. J. Teale, Biochim. Biophys. Acta, 1959, 35, 543.
- 7 C. A. Yu and I. C. Gunsalus, J. Biol. Chem., 1974, 249, 107-110.
- 8 G. C. Wagner, I. C. Gunsalus, M. Y. R. Wang and B. M. Hoffman, *J. Biol. Chem.*, 1981, 256, 6266–6273.
- 9 D. S. Lee, A. Yamada, H. Sugimoto, I. Matsunaga, H. Ogura, K. Ichihara, S. Adachi, S. Y. Park and Y. Shiro, *J. Biol. Chem.*, 2003, 278, 9761–9767.
- O. Shoji, C. Wiese, T. Fujishiro, C. Shirataki, B. Wünsch and Y. Watanabe, *JBIC*, *J. Biol. Inorg. Chem.*, 2010, 15, 1109–1115.
- 11 M. S. Hargrove, D. Barrick and J. S. Olson, *Biochemistry*, 1996, 35, 11293–11299.
- I. C. Gunsalus and G. C. Wagner, *Methods Enzymol.*, 1978, 52, 166–188.
- 13 S. C. Harrison and E. R. Blout, J. Biol. Chem., 1965, 240, 299-303.

- 14 G. C. Wagner, M. Perez, W. A. Toscano and I. C. Gunsalus, J. Biol. Chem., 1981, 256, 6262–6265.
- 15 E. M. Harvat, O. Daltrop, F. Sobott, M. Moreau, P. D. Barker, J. M. Stevens and S. J. Ferguson, *Metallomics*, 2011, 3, 363–368.
- 16 E. A. Berry and B. L. Trumpower, Anal. Biochem., 1987, 161, 1–15.
- 17 M. M. Bradford, Anal. Biochem., 1976, 72, 248-254.
- 18 G. D. Depillis, B. P. Sishta, A. G. Mauk and P. R. O. Demontellano, J. Biol. Chem., 1991, 266, 19334–19341.
- K. Kitanishi, J. Igarashi, K. Hayasaka, N. Hikage, I. Saiful, S. Yamauchi, T. Uchida, K. Ishimori and T. Shimizu, *Biochemistry*, 2008, 47, 6157–6168.
- 20 W. Pfeil, B. O. Nolting and C. Jung, *Biochemistry*, 1993, 32, 8856–8862.
- 21 O. Shoji, T. Fujishiro, H. Nakajima, M. Kim, S. Nagano, Y. Shiro and Y. Watanabe, *Angew. Chem., Int. Ed.*, 2007, **46**, 3656–3659.
- 22 O. Shoji and Y. Watanabe, Metallomics, 2011, 3, 379-388.
- 23 M. H. Gelb, W. A. Toscano and S. G. Sligar, *Proc. Natl. Acad. Sci. U. S. A.*, 1982, **79**, 5758–5762.
- 24 O. Daltrop and S. J. Ferguson, J. Biol. Chem., 2004, 279, 45347-45353.
- 25 T. Matsui, S. Nagano, K. Ishimori, Y. Watanabe and I. Morishima, *Biochemistry*, 1996, **35**, 13118–13124.
- 26 V. Y. Uvarov, V. E. Tretiakov and A. I. Archakov, *FEBS Lett.*, 1990, **260**, 309–312.